Literature DB >> 27653223

Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?

Milton Packer1.   

Abstract

Entities:  

Year:  2016        PMID： 27653223     DOI： 10.1001/jamacardio.2016.3053

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  3 in total

1.  Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.

Authors:  Lindsey R Sangaralingham; S Jeson Sangaralingham; Nilay D Shah; Xiaoxi Yao; Shannon M Dunlay
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

2.  Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.

Authors:  Nancy Luo; Steven J Lippmann; Robert J Mentz; Melissa A Greiner; Bradley G Hammill; N Chantelle Hardy; Warren K Laskey; Paul A Heidenreich; Chun-Lan Chang; Adrian F Hernandez; Lesley H Curtis; Pamela N Peterson; Gregg C Fonarow; Emily C O'Brien
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

3.  Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure.

Authors:  Birju R Rao; Candace D Speight; Larry A Allen; Scott D Halpern; Yi-An Ko; Daniel D Matlock; Miranda A Moore; Alanna A Morris; Laura D Scherer; Mary C Thomson; Peter Ubel; Neal W Dickert
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.